← Sandoz overview

Sandoz vs Amneal Pharmaceuticals, Inc. Class A Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sandoz Group AG (SDZ.SW)

Q3 2026
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

August 2026
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Latest
▲3▼1

Sandoz bets big on biosimilars as US tariff threat looms

  • US 100% generic tariff threat Trump threatened 100% tariffs on generic medicines, a direct risk to Sandoz's low-margin generics business. Its CEO warned tariffs would not bring production to the US and could disrupt supply of vital medicines, weighing on the shares.

    A major policy threat to Sandoz's core generics business and a real counterweight to the positive news.

  • Strong H1 results and raised margin guidance First-half sales rose 10% to $5.76bn, with biosimilars up 25% and now a third of sales. Profit margins expanded and full-year margin guidance was raised, showing the biosimilar bet is paying off and supporting the shares.

    Hard financial results that confirm the growth story and underpin the stock.

  • Bio100 strategy and pipeline expansion Sandoz unveiled Bio100, aiming to lead biosimilars by 2040 with over 100 products and to more than double sales in a decade. It added a Henlius partnership worth up to $322m and a $300m Slovenia plant, giving investors a long-term growth plan.

    The strategy and pipeline deals set the long-term direction that drives the investment case.

  • New market approvals and Thailand talks Brazil approved Sandoz's semaglutide diabetes drug Owozy for launch in a $1.8bn market, and Thailand plans a cooperation deal within weeks to draw Sandoz investment. Both widen its reach, though near-term financial impact is limited.

    Shows geographic expansion that adds future sales, a smaller but genuine positive driver.

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)

Q3 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

August 2026
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.

Latest
▲3▼1

Amneal's record quarter and Kashiv biosimilars deal offset by weak growth warnings

  • Record Q2 results and raised guidance Amneal reported record Q2 revenue of $796 million, up 10% year-over-year, and raised full-year guidance for the second time in 2026. Adjusted EPS rose 20% and margins improved, showing the core business is growing and more profitable than expected, which supports a higher stock price.

    This is the strongest new positive fundamental event, directly lifting earnings expectations and investor confidence.

  • Kashiv acquisition opens biosimilars market Amneal completed its purchase of Kashiv BioSciences, giving it full control over biosimilar development and manufacturing. Biosimilars are copycat versions of expensive biologic drugs, a market that could exceed $300 billion as patents expire. This adds a new long-term growth engine beyond generics.

    The deal is a new strategic move that expands Amneal's addressable market and future revenue potential.

  • FDA approval expands iohexol contrast agent line Amneal won FDA approval for additional strengths and vial sizes of iohexol injection, a generic contrast dye used in medical scans. The expanded lineup now covers most of a $706 million U.S. market, with launch planned for Q3 2026. This adds near-term product revenue.

    New regulatory approval directly enables additional sales and market share in an existing product category.

  • Weak long-term growth and low returns raise caution Analysts flagged Amneal's projected revenue growth of just 2.6% over the next year, down sharply from 8.7% historically. Free cash flow margin has been flat at 8.9% for five years, and return on invested capital averages only 4.9%, below the cost of capital. This suggests limited upside and possible downside at current valuation.

    This is the main counterweight, highlighting structural concerns that could cap the stock's gains despite recent positive news.